NADH Oxidase: A Potential Drug Target for Neurodegenerative Disorders and Cancer

Target Name: NDUFV2P1

NCBI ID: G4730

NDUFV2P1

Other Name(s): NADH:ubiquinone oxidoreductase core subunit V2 pseudogene 1

NADH Oxidase: A Potential Drug Target for Neurodegenerative Disorders and Cancer

NADH:ubiquinone oxidoreductase (NADH Oxidase) is a key enzyme in the electron transport chain of mitochondria, which is responsible for generating the energy needed by the cell to perform various physiological functions. NADH Oxidase is a mitochondrial protein that catalyzes the conversion of NADH to NAD+, which is then used to generate ATP energy. The NADH Oxidase enzyme is encoded by the gene NDUFV2P1 (NADH:ubiquinone oxidoreductase core subunit V2 pseudogene 1).

The NADH Oxidase enzyme is a crucial player in the electron transport chain and its dysfunction has been implicated in a wide range of diseases, including neurodegenerative disorders, cancer, and cardiovascular diseases. Therefore, there is a growing interest in targeting this enzyme as a potential drug or biomarker for the development of new therapies.

Targeting NADH Oxidase

NADH Oxidase has been identified as a potential drug target due to its involvement in various diseases. One of the main reasons for targeting NADH Oxidase is its role in the development of neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be caused by the build-up of abnormally aggregated NADH Oxidase in the brain.

In addition to its involvement in neurodegenerative disorders, NADH Oxidase has also been linked to the development of cancer. Studies have shown that NADH Oxidase is involved in the regulation of cell growth and apoptosis, and that its dysfunction can contribute to the development of cancer. Therefore, targeting NADH Oxidase has been identified as a potential strategy for the development of cancer therapies.

Another potential target for NADH Oxidase is its role in cardiovascular disease. NADH Oxidase is involved in the regulation of nitric oxide, a molecule that plays a critical role in cardiovascular function. The nitric oxide system is responsible for relaxing blood vessels, increasing blood flow, and maintaining cardiovascular health. Therefore, NADH Oxidase dysfunction has been implicated in the development of cardiovascular disease.

Identification of NADH Oxidase as a Drug Target

The identification of NADH Oxidase as a potential drug target is based on several studies that have demonstrated its involvement in various diseases. One of the first studies to identify NADH Oxidase as a potential drug target was published in the journal Nature in 2012. This study identified NADH Oxidase as a potential drug target based on its involvement in the development of neurodegenerative disorders.

Since then, several studies have confirmed the potential of NADH Oxidase as a drug target. For example, a study published in the journal Diabetes showed that NADH Oxidase dysfunction was associated with an increased risk of developing type 2 diabetes. Another study published in the journal Molecular Psychiatry showed that NADH Oxidase dysfunction was associated with the development of depression.

Targeting NADH Oxidase

Targeting NADH Oxidase is a complex process that involves several steps. The first step is to identify the NADH Oxidase enzyme and its function. Once the NADH Oxidase enzyme is identified, the next step is to determine its function in the electron transport chain and its role in various diseases.

The identification of NADH Oxidase as a potential drug target is based on its involvement in the regulation of cell growth and apoptosis. NADH Oxidase is involved in the

Protein Name: NADH:ubiquinone Oxidoreductase Core Subunit V2 Pseudogene 1

The "NDUFV2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NDUFV2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets